Asthma – Unmet Need – Detailed, Expanded Analysis (US/EU)
Several effective anti-inflammatory agents and bronchodilators are available for controlling patients’ mild or moderate asthma. However, despite the availability of LAMAs (e.g., Boehringer-Ingelheim’s Spiriva), LABA/LAMA/ICS FDCs (e.g., GSK’s Trelegy, Chiesi’s Trimbow), and novel biologics (e.g., AstraZeneca’s Fasenra, Teva’s Cinqair / Cinqaero, Sanofi / Regeneron’s Dupixent, GSK’s Nucala) in the market, there is still an unmet need for effective therapies for severe disease, especially for patients whose symptoms are not adequately controlled with current therapies or who depend on frequent SABA and/or oral corticosteroid use to achieve relief. This Unmet Need report provides quantitative insights into key treatment drivers and goals and the current level of unmet need in severe asthma, based on the perceptions of U.S. and European physicians. We analyze the commercial opportunities and how emerging therapies may capitalize on these opportunities.
For the abstract please provide an overview paragraph here and then fill in the bulleted sections below. Feel free to modify the bulleted section. Leverage content from a brochure if you have one.
QUESTIONS ANSWERED
- What are the treatment drivers and goals for severe asthma?
- What drug attributes are key influences, which have limited impact, and which are hidden opportunities?
- How do current therapies perform on key treatment drivers and goals for severe asthma?
- What are the prevailing areas of unmet need and opportunity in severe asthma?
- What trade-offs across different clinical attributes and price are acceptable to U.S. and European physicians for a hypothetical new severe asthma drug?
PRODUCT DESCRIPTION
Provides quantitative insight into U.S. and European physician perceptions of key treatment drivers and goals and the current level of unmet need for a specific disease. Commercial opportunities are analyzed, and the extent to which emerging therapies may capitalize on these opportunities is evaluated.
Markets covered: United States, United Kingdom, France, Germany
Primary research: Survey of 31 U.S. pulmonologists, 30 U.S. allergists, and 31 European pulmonologists fielded in March 2021
Key companies: Roche, GlaxoSmithKline, AstraZeneca, Novartis, Chiesi, Boehringer-Ingelheim, Sanofi, Regeneron
Key drugs: Xolair, Nucala, Fasenra, Dupixent, Spiriva (tiotropium), LABA/ICS FDCs, LABA/LAMA/ICS FDCs
Table of contents
- Asthma - Unmet Need - Detailed, Expanded Analysis (US/EU)
- Executive Summary
- Unmet Need - Severe Asthma - Executive Summary - June 2021
- Introduction
- Overview
- Methodology
- Rationale for Treatment Drivers and Goals Selection
- Rationale for Drug Selection
- Products / Regimens for Severe Asthma and Rationale for Drug Selection
- Treatment Drivers and Goals
- Key Findings: Attribute Importance
- Relative Importance of Efficacy, Safety and Tolerability, Convenience of Administration, and Nonclinical Attributes to Surveyed Pulmonologists' and Allergists' Prescribing Decisions in Severe Asthma
- Importance of Efficacy Attributes to Prescribing Decisions in Severe Asthma: United States - Pulmonologists
- Importance of Efficacy Attributes to Prescribing Decisions in Severe Asthma: United States - Allergists
- Importance of Efficacy Attributes to Prescribing Decisions in Severe Asthma: Europe
- Importance of Safety and Tolerability Attributes to Prescribing Decisions in Severe Asthma: United States - Pulmonologists
- Importance of Safety and Tolerability Attributes to Prescribing Decisions in Severe Asthma: United States - Allergists
- Importance of Safety and Tolerability Attributes to Prescribing Decisions in Severe Asthma: Europe
- Importance of Convenience of Administration Attributes to Prescribing Decisions in Severe Asthma: United States - Pulmonologists
- Importance of Convenience of Administration Attributes to Prescribing Decisions in Severe Asthma: United States - Allergists
- Importance of Convenience of Administration Attributes to Prescribing Decisions in Severe Asthma: Europe
- Importance of Nonclinical Factors to Prescribing Decisions in Severe Asthma: United States - Pulmonologists
- Importance of Nonclinical Factors to Prescribing Decisions in Severe Asthma: United States - Allergists
- Importance of Nonclinical Factors to Prescribing Decisions in Severe Asthma: Europe
- Key Findings: Stated vs. Derived Importance
- Stated vs. Derived Importance of Key Efficacy, Safety and Tolerability, Convenience of Administration, and Nonclinical Attributes to Prescribing Decisions in Severe Asthma: United States - Pulmonologists
- Stated vs. Derived Importance of Key Efficacy, Safety and Tolerability, Convenience of Administration, and Nonclinical Attributes to Prescribing Decisions in Severe Asthma: United States - Allergists
- Stated vs. Derived Importance of Key Efficacy, Safety and Tolerability, Convenience of Administration, and Nonclinical Attributes to Prescribing Decisions in Severe Asthma: Europe
- Product Performance Against Treatment Drivers and Goals
- Key Findings
- Overall Performance of Key Therapies for Severe Asthma: United States - Pulmonologists
- Overall Performance of Key Therapies for Severe Asthma: United States - Allergists
- Overall Performance of Key Therapies for Severe Asthma: Europe
- Mean Overall Performance of Key Therapies for Severe Asthma: United States and Europe
- Relative Performance of Key Therapies for Severe Asthma Across Select Efficacy Attributes: United States - Pulmonologists
- Relative Performance of Key Therapies for Severe Asthma Across Select Efficacy Attributes: United States - Allergists
- Relative Performance of Key Therapies for Severe Asthma Across Select Efficacy Attributes: Europe
- Relative Performance of Key Therapies for Severe Asthma Across Select Safety and Tolerability Attributes: United States - Pulmonologists
- Relative Performance of Key Therapies for Severe Asthma Across Select Safety and Tolerability Attributes: United States - Allergists
- Relative Performance of Key Therapies for Severe Asthma Across Select Safety and Tolerability Attributes: Europe
- Relative Performance of Key Therapies for Severe Asthma Across Select Convenience of Administration Attributes: United States - Pulmonologists
- Relative Performance of Key Therapies for Severe Asthma Across Select Convenience of Administration Attributes: United States - Allergists
- Relative Performance of Key Therapies for Severe Asthma Across Select Convenience of Administration Attributes: Europe
- Relative Performance of Key Therapies for Severe Asthma Across Select Nonclinical Attributes: United States - Pulmonologists
- Relative Performance of Key Therapies for Severe Asthma Across Select Nonclinical Attributes: United States - Allergists
- Relative Performance of Key Therapies for Severe Asthma Across Select Nonclinical Attributes: Europe
- Assessment of Unmet Need
- Key Findings: Unmet Need in Severe Asthma
- Surveyed Pulmonologists' Satisfaction with the Performance of Key Therapies for Severe Asthma on Efficacy, Safety and Tolerability, Convenience of Administration, and Nonclinical Factors: United States
- Surveyed Allergists' Satisfaction with the Performance of Key Therapies for Severe Asthma on Efficacy, Safety and Tolerability, Convenience of Administration, and Nonclinical Factors: United States
- Surveyed Pulmonologistsu2019 Satisfaction with the Performance of Key Therapies for Severe Asthma on Efficacy, Safety and Tolerability, Convenience of Administration, and Nonclinical Factors: Europe
- Surveyed Pulmonologists' Ascribed Level of Unmet Need Across Key Efficacy Attributes in Severe Asthma: United States
- Surveyed Allergists' Ascribed Level of Unmet Need Across Key Efficacy Attributes in Severe Asthma: United States
- Surveyed Pulmonologists' Ascribed Level of Unmet Need Across Key Efficacy Attributes in Severe Asthma: Europe
- Surveyed Pulmonologists' Ascribed Level of Unmet Need Across Key Safety and Tolerability Attributes in Severe Asthma: United States
- Surveyed Allergists' Ascribed Level of Unmet Need Across Key Safety and Tolerability Attributes in Severe Asthma: United States
- Surveyed Pulmonologists' Ascribed Level of Unmet Need Across Key Safety and Tolerability Attributes in Severe Asthma: Europe
- Surveyed Pulmonologists' Ascribed Level of Unmet Need Across Key Convenience of Administration Attributes in Severe Asthma: United States
- Surveyed Allergists' Ascribed Level of Unmet Need Across Key Convenience of Administration Attributes in Severe Asthma: United States
- Surveyed Pulmonologists' Ascribed Level of Unmet Need Across Key Convenience of Administration Attributes in Severe Asthma: Europe
- Surveyed Pulmonologists' Ascribed Level of Unmet Need Across Key Nonclinical Factors in Severe Asthma: United States
- Surveyed Allergists' Ascribed Level of Unmet Need Across Key Nonclinical Factors in Severe Asthma: United States
- Surveyed Pulmonologists' Ascribed Level of Unmet Need Across Key Nonclinical Factors in Severe Asthma: Europe
- Key Findings: Unmet Need in Severe Asthma and Related Indications
- Surveyed Pulmonologists' Ascribed Level of Unmet Need in Severe Asthma and Related Indications: United States
- Surveyed Allergists' Ascribed Level of Unmet Need in Severe Asthma and Related Indications: United States
- Surveyed Pulmonologists' Ascribed Level of Unmet Need in Severe Asthma and Related Indications: Europe
- Opportunity Analysis
- Areas of Opportunity in the Severe Asthma Market and Emerging Therapy Insights
- Opportunity: Treatments with Robust Efficacy in Reducing Exacerbation Rates
- Opportunity: Treatments Offering Less Burdensome Administration
- Opportunity: Treatments with Demonstrated Efficacy in Patients with Non-TH2 Asthma
- Areas of Opportunity in the Severe Asthma Market and Emerging Therapy Insights
- Target Product Profiles
- Assessing Drug Development Opportunities
- Target Product Profile Methodology
- Attributes and Attribute Levels
- Attributes of Key Current and Late-Phase Emerging Therapies for Severe Asthma
- Attribute Importance and Part-Worth Utilities
- Severe Asthma Target Product Profile: Attribute Importance
- Decrease in Annual Asthma Exacerbation Rate in TH2-High (e.g., u2265 300 Eosinophils / u00b5L Blood) Subpopulation (%, Placebo-Adjusted)
- Decrease in Annual Asthma Exacerbation Rate in TH2-Low (e.g., < 150 Eosinophils / u00b5L Blood) Subpopulation (%, Placebo-Adjusted)
- Improvement in Baseline FEV1 at 24 Weeks (mL, Placebo-Adjusted)
- Percentage of Patients With u226550% Reduction in OCS Use at 24 Weeks (%, Placebo-Adjusted)
- Rate of Severe Adverse Events Over 48 Weeks (% of Patients, Placebo-Adjusted)
- Dosing Burden (Drug Formulation and Frequency)
- Price per Day
- Conjoint Analysis-Based Simulation of a Market Scenario
- Severe Asthma Market Simulation: Share of Preference of Target Product Profiles Included in the Market Scenario
- Severe Asthma Market Simulation: Likelihood to Prescribe Target Product Profiles Included in the Market Scenario
- Severe Asthma Market Simulation: Target Product Profiles Included in the Market Scenario
- Appendix
- Key Abbreviations
- Experts Interviewed
- Bibliography
- Executive Summary
Shubhendu Ghosh, Ph.D., is a senior business insights analyst on the Immune and Inflammatory Disorders team at Clarivate. His focus is the asthma therapy market. Previously, Dr. Ghosh was an associate editor at Nature Structural & Molecular Biology and a copy editor at Nature Medicine. He was also a scientific and developmental editor at Nature Research Editing Service. He holds a Ph.D. in biomedical sciences from the University of Massachusetts Medical School, a B.Sc. in microbiology from Delhi University, and an M.Sc. in biotechnology from Madurai Kamaraj University.